Comparative Pharmacology
Head-to-head clinical analysis: ABRILADA versus IDACIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABRILADA versus IDACIO.
ABRILADA vs IDACIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including changes in adhesion molecules, chemotaxis, and apoptosis.
IDACIO is a biosimilar to adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-alpha) and blocks its interaction with p55 and p75 cell surface TNF receptors. This neutralizes the pro-inflammatory effects of TNF-alpha, including cytokine release, adhesion molecule expression, and immune cell activation.
80 mg subcutaneously every other week. For patients weighing ≥100 kg, 80 mg every week.
40 mg subcutaneously once weekly. If methotrexate is not tolerated, monotherapy may be considered.
None Documented
None Documented
Terminal elimination half-life approximately 10–14 days in adults, supporting every-other-week dosing; may be shorter in pediatric patients.
Terminal elimination half-life is approximately 11-17 days (mean 14 days). Supports every-other-week dosing for maintenance of therapeutic concentrations.
Primarily degraded into amino acids and recycled or excreted in urine (less than 1% unchanged); no significant biliary/fecal elimination.
Primarily degraded to amino acids via catabolic pathways; renal excretion of intact drug is negligible (<1%). No significant biliary or fecal elimination of active drug.
Category C
Category C
TNF-Alpha Inhibitor
TNF-Alpha Inhibitor